Intelligence Report · ~14 min read
Psychiatry · Major Depressive Disorder Competitive Landscape
2 findings · 50 signals · 5 insights
Type
Competitive Landscape ReportGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 77%
Evidence
52 items
Sources
1
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Competitive landscape assessment for Psychiatry · Major Depressive Disorder synthesizes 2 Competitiva findings across 50 active signals. 0 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.
Key Developments
Material intelligence events ranked by strategic relevance.
- competitive
Roche — Truvada
Roche is a regulatory competitive threat because recent agency-facing activity on Truvada in Psychiatry · Mental Health may reset approval benchmarks and timeline expectations for Pfizer.
View detail - competitive
Roche — Truvada
Roche is a regulatory competitive threat because recent agency-facing activity on Truvada in Psychiatry · Mental Health may reset approval benchmarks and timeline expectations for Pfizer.
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Monitor 0 high-pressure competitive programs for portfolio displacement risk. Cross-reference 5 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Roche — Truvada
77%Roche is a regulatory competitive threat because recent agency-facing activity on Truvada in Psychiatry · Mental Health may reset approval benchmarks and timeline expectations for Pfizer.
Source: Roche
View evidenceRoche — Truvada
77%Roche is a regulatory competitive threat because recent agency-facing activity on Truvada in Psychiatry · Mental Health may reset approval benchmarks and timeline expectations for Pfizer.
Source: Roche
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients
Trial Update
- University of Maryland Evaluates Suvorexant for Reducing Drug Demand
Trial Update
- Post-ICU PTSD Intervention Shows Potential for Improving Quality of Life
Trial Update
- Heritage Pharma's Sertraline Hydrochloride ANDA077345 Receives AP Status
Regulatory Approval
- Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety Trial Initiated
Trial Update
- FDA Grants Approval for Lurasidone Hydrochloride ANDA208047 by Dr. Reddy's
Regulatory Approval
- Phase II Trial of Teleo Virtual Therapy Platform for Youth Psychotherapy Engagement
Trial Update
- Aurobindo Pharma's Olanzapine ANDA203708 Receives AP Status from FDA
Regulatory Approval
Insights
- FDA Acceptance of Fluoxetine Hydrochloride Signals Competitive Shift in Antidepressants
Psychiatry · Antidepressant
- Emerging Generic Competition in Psychiatry: Strategic Implications for Market Leaders
Psychiatry · SNRI
- Emerging Insights in Pediatric Mental Health: Implications for Treatment Strategies
Psychiatry · PTSD
- Emerging Opportunities in Psychiatry: Innovations in Treatment and Regulatory Landscape
Psychiatry · Stress and Anxiety
- Torrent Pharmaceuticals Gains Competitive Edge with Lurasidone Hydrochloride Approval
Psychiatry · Antipsychotic
Companies
- Pfizer
140 signals
- Eli Lilly
78 signals
- Hikma
30 signals
- Aurobindo Pharma
28 signals
- Sciegen Pharmaceuticals
15 signals
- Alembic Pharmaceuticals
14 signals
- Zydus Pharmaceuticals
11 signals
- Amneal Pharmaceuticals
9 signals